

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Andrew L. DARROW, Jenson QI and Patricia ANDRADE-GORDON

Serial No.:

Not Assigned

Art Unit:

Not Assigned

Filed:

10 December 2001

Examiner:

Not Assigned

For:

**ZYMOGEN ACTIVATION SYSTEM** 

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

10 December 2001

(Date of Deposit)

John W. Wallen, III, Esq.
(Name of applicant, assignee, or Registered Representative)

(Signature)

10 December 2001

(Date of Signature)

Assistant Commissioner for Patents Washington, D.C. 20231

#### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

$\boxtimes$	In accordance with §1.97(b), since this Information Disclosure Statement is being
	filed either within three months of the filing date of the above-identified national
	application (other than a continued prosecution application under §1.53(d)),
	within three months of the date of entry into the national stage of the above
	identified application as set forth in \$1.491, or before the mailing date of a first
	Office Action on the merits of the above-identified application, or before the
	mailing date of a first Office Action after the filing of a request for continued
	examination under §1.114, no additional fee is required.
	•
	In accordance with §1.129(a), this Information Disclosure Statement is being

therefore:	
	Statement in Accordance with §1.97(e) (attached); or
П	Please charge Deposit Account No. 10-0750/ORT-

filed in connection with [ ] the first or [ ] second After Final Submission,

XXXX/JWW the fee of \$180.00 as set forth in \$1.17(p).

	In accorda	ago with \$1,07(a) this Information Disabases Clatered in Line (i)					
Ш		In accordance with \$1.97(c), this Information Disclosure Statement is being filed					
		eriod set forth in \$1.97(b) above but before the mailing date of either a					
	Final Actio	on under §1.113 or a Notice of Allowance under §1.311, or an action					
	that otherv	vise closes prosecution and that it is accompanied by one of:					
		Statement in Accordance with §1.97(e) (attached); or					
		Please charge Deposit Account No. 10-0750/ORT-					
		XXXX/JWW the fee of \$180.00 as set forth in \$1.17(p).					
	after the r Allowance hereby pet Included a	nace with \$1.97(d), this Information Disclosure Statement is being filed mailing date of either a Final Action under \$1.113 or a Notice of under \$1.311 but before the payment of the Issue Fee. Applicant(s) ition(s) for consideration of this Information Disclosure Statement. re: Statement in Accordance with \$1.97(e) as set forth below and the 00 as set forth in \$1.17(p).					
$\boxtimes$		each of the references listed on the attached Form PTO-1449 are erewith, EXCEPT THAT:					
		In view of the voluminous nature of references, and since all references cited on the attached form PTO-1449 are of record in the Parent Application Serial No.: 09/386,642,					
		and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.					
		Enumer, copies are not enclosed herewill.					

	<b>,</b> .	If any of the foregoing p	ublications are not available to the
		Examiner, Applicant wil	l endeavor to supply copies at the
		Examiner's request.	
	There are no l	isted references which are	e not in the English language.
	The relevance as follows:	e of those listed references	s which are not in the English language is
		copies of search report(s) ed on the attached Submis	from corresponding patent application(s), ssion Under MPEP 609 D.
			shed pending patent applications which isted on the attached Submission Under
Ple	ease charge any	deficiency or credit any	overpayment to Deposit Account No. 10-
0750/OR	Γ-1552/JWW.	This form is submitted in	triplicate.
			Respectfully submitted,
			John W. Wallen, III, Esq. Reg. No. 35,403 Attorney for Applicants
Johnson &	z Johnson		

One Johnson & Johnson Plaza New Brunswick, New Jersey 08933-7003 (858) 784-3239

DATE: 10 December 2001

#### SUBMISSION UNDER MPEP 609 D

Page 1 of 3

Application Number	Not Assigned .
Filing Date	10 December 2001
First Named Inventor	DARROW
Group Art Unit	Not Assigned
Examiner Name	Not Assigned
Attorney Docket Number	ORT-1552

# 10/015989 10/015989 12/10/01

#### **U.S. PATENT DOCUMENTS**

Examiner	Cite	- FF	U.S. Patent Do	Pages Calumna Lines	
Initials	No.1		Number	Kind Code <sup>2</sup> (if known)	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Bang et al.	US 4,992,373		
		Bang et al.	US 5,196,322		
		Forster et al.	US 5,200,340		
		Van Eekelen et al.	US 5,217,878		
		Gerlitz et al.	US 5,270,178		
		Samal et al.	US 5,278,062		
		Berg et al.	US 5,326,700		<u>-</u>
		Mosher et al.	US 5,342,762		
		Lavallie, Edward R.	US 5,665,566		
		Comb et al.	US 5,834,247		

#### FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document Offices Numbers KindCodes or rel				Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		SmithKline Beecham PLC	PCT	EP 0887414			
		Boehringer Mannheim GmbH	PCT	WO 97/ 47737			
		Symbiosis Genetics, Inc.	PCT	WO 98/ 49326	-		-

#### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
		Altschul et al., (1990) Basic Local Alignment.	
		I. Ausubel and M. Frederick, "Short Protocols in Molecular Biology", Molecular biology-Laboratory Manuals (1997).	
		<u>Chen</u> et al., "Expression and Activity-Dependent Changes of a Novel Limbic-Serine Protease Gene in the Hippocampus", J. Neurosci. (1995) 15: 5088-5097.	
	<u>Davie</u> et al., "The Coagulation Cascade: Initiation, Maintenance, and Regulation.", <i>Biochemistry</i> (1991) <b>30</b> :10363-10370		
		Hansson et al., "Cloning, Expression, and Characterization of Stratum Corneum Chymotryptic Enzyme: A Skin-Specific Human Serine Proteinase", J. Biol. Chem. (1994) 269:19420-19426.	
		R. Huber and W. Bode, "Structural Basis of the Activation and Action of Trypsin", Acc. Chem. Res. (1978) 11:114-122.	
		Inoue et al., "Cloning and Tissue Distribution of a Novel Serine Protease Esp-1 from Human Eosinophils", Biochem. Biophys. Res. Commun. (1998) 252:307-312.	

Examiner	Date
Signature	Considered

## SUBMISSION UNDER MPEP 609 D

Page 2 of 3

Application Number	Not Assigned		
First Named Inventor	DARROW		
Attorney Docket Number	ORT-1552		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Ishii et al., "Kinetics of Thrombin Receptor Cleavage on Intact Cells. Relation to Signaling", J. Biol. Chem. (1993) 268:9780-9786.	
		Kossiakoff et al., "Structure of Bovine Trypsinogen at 1.9 .ang. Resolution", Biochemistry (1977) 16:654-664.	
		S. Kühn and P. F. Zipfel, "The Baculovirus Expression Vector pBSV-8His Directs Secretion of Histidine-Tagged Proteins", Gene (1995) 12:225-229.	
		J. Kyte and R. F. Doolittle, "A Simple Method for Displaying the Hydropathic Character of a Protein", J. Mol. Biol. (1982) 157:105-132.	
		Leytus et al., "A Novel Trypsin-Like Serine Protease (Hepsin) with a Putative Transmembrane Domain Expressed by Human Liver and Hepatoma Cells", Biochemistry (1988) 27:1067-1074.	
		Little et al., "Zyme, A Novel and Potentially Amyloidogenic Enzyme cDNA Isolated from Alzheimer's Disease Brain", J. Biol. Chem. (1997) 272:25135-25142.	
		B. Martoglio and R. Dobberstein, "Signal Sequences: More Than Just Greasy Peptides", Trends Cell Biol. (1998) 8:410-415.	
		Matthews et al., "Three-Dimensional Structure of Tosylalpha Chymotrypsin", Nature (London) (1967) 214:652-656.	
		Nelson et al., "Molecular Cloning and Characterization of Prostase, An Androgen-Regulated Serine Protease with Prostate-Restricted Expression", P. N. A. S. USA (1999) 96:3114-3119.	
·		W. R. Pearson and D. J. Lipman, "Improved Tools for Biological Sequence Comparison", P. N. A. S. USA (1988) 85:2444-2448.	
		Pham et al., "Production of Fully Active Recombinant Murine Granzymen B in Yeast", J. Biol. Chem. (1988) 273(3):1629-1698.	
		D. Proud and A. P. Kaplan, "Kinin Formation: Mechanisms and Role in Inflammatory Disorders", Ann. Rev. Immunol. (1988) 6:49-83.	
	-	N. D. Rawlings and A. J. Barrett, "Families of Serine Peptidases", Methods Enzymol. (1994) 244:19-61.	
		K. B. M. Reid and R. R. Porter, "The Proteolytic Activation Systems of Complement", Ann. Rev. Biochem. (1981) 50:433-464.	
		Sambrook et al., Molecular Cloning: A Laboratory Manual, 2 <sup>nd</sup> Ed. (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989)).	
		Sherman et al., "Identification of Tissue-type Plasminogen Activator-specific Plasminogen Activator Inhibitor-1 Mutants", J. Biol. Chem. (1995) 270(16):9301-9306.	
		Stroud et al., "Structure of Bovine Trypsin: Electron Density Maps of the Inhibited Enzyme at 5 .ang. and 2.7 .ang. Resolution", J. Mol. Biol. (1974) 83:185-208.	

Examiner	Date	
Signature	 Considered	

# SUBMISSION UNDER MPEP 609 D Page 3 of 3 Application Number Not Assigned First Named Inventor DARROW Attorney Docket Number ORT-1552

#### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		K. Tachias and E. L. Madison, "Converting Tissue-Type Plasminogen Activator into a Zymogen", J. Biol. Chem. (1996) 271:28749-28752.	
		<u>Takayama</u> et al., "Characterization of the Precursor of Prostate-Specific Antigen Activation by Trypsin and by Human Glandular Kallikrein", J. Biol. Chem. (1997) 272:21582-21588.	
		Wang et al., "Production of Active Recombinant Human Chymase from a Construct Containing the Enterokinase Cleavage Site of Trypsinogen in Place of the Native Propeptide Sequence", Biol. Chem. Hoppe-Seyler (1995) 376:681-684.	
		Yamashiro et al., "Molecular Cloning of a Novel Trypsin-Like Serine Protease (Neurosin) Preferentially Expressed in Brain", Biochim. Biophys. Acta (1997) 1350:11-14.	
		Yoshida et al., "Sequence Analysis and Expression of Human Neuropsin cDNA and Gene.", Gene (1998) 213:9-16.	
		Yoshida et al., "cDNA Cloning and Expression of a Novel Serine Protease, TLSP1", Biochim. Biophys. Acta (1998) 1399:225-228.	
		Yu et al., "Molecular Cloning: Tissue Specific Expression and Cellular Localization of Human Prostasin mRNA", J. Bio. Chem. (1995) 270(22): 13483-13489.	
		Yu et al., "Prostasin is a Novel Human Serine Proteinase from Seminal Fluid: Purification, Tissue Distribution and Localization in Prostate Gland", J. Biol. Chem. (1994) 269:18843-8.	

Examiner	Date
Signature	Considered